Tuesday, June 17, 2008 12:40:48 PM
Author: akasidney86 send pm · add member to favs · ignore · recommend
Recs: 139 My email to Andy
Dr. von Eschenbach:
Your decision regarding Provenge is an unmitigated disaster on so many levels:
1. Biotech funding: this will further reduce funding of biotech, arguably the major component, within a free-market economy, of new solutions to very complex health problems.
2. Status of the FDA within the world medical community: it makes you personally and the office of the Director of the FDA a person/position of zero credibility given your repeated comments about the 'new, bridge-building FDA', and thus hurts patients around the world who look towards the U.S. and the FDA for leadership.
3. New medical thinking and breakthroughs: it encourages the obvious, deliterious and widely commented predatory tactics practiced by the hedge fund community of shorting and pressuring developmental biotechs... with only one outcome... fewer successful drugs on the market.
4. Effect on internal FDA policy; It strengthens those who would serve and who live off of Big Pharma and the money it generates, while weakening those who would, while respecting to the letter the stated policy of the FDA, offer a pathway to approval for drugs in terminal disease applications.
5. The effect on patients suffering terminal diseases: it states that, from the FDA's point of view, there is no difference between a potentially lifesaving treatment and a toe fungus medicine... terrible news for all those who need hope in a desperate struggle.
6. The question of the risk<>benefit relationshipand it's current meaning within the FDA: This treatment was turned down in spite of a panel which unanimously stated that it carries no health risk. Therefore, how possibly can the risk/reward ratio be negative if there is no risk and clear reward.
7. The FDA approval process as a whole: as there was no new information disclosed through the FDA vetting process, that can only mean that the information that the FDA denied the BLA on was exactly the same information that it allowed Dendreon to file under. What is the point of that?
8. The importance and viability of the Advisory Committee process: the BLA was voted by the most prestigious authorities the FDA itself could find safe and eficacious... and then ignored. This can only hurt this vital process, the only part of the process actually open to the people that the FDA is supposed to be serving, the public.
9. The importance of patients and patient advocates within the FDA approval process: All of the recognized Prostate Cancer groups supported the Provenge BLA... and were ignored. The FACT that Dr. Maha Hussain actually fell asleep during the disregarded Advisory Committee meeting speaks volumes.
For these reasons and many, many more, your decision to deny the Provenge BLA is simply unconscionable, and we the people will pay the price for many, many years to come.
signed xxxxx
http://investorvillage.com/smbd.asp?mb=971&mn=107543&pt=msg&mid=2105357
Recent RPRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 12:39:00 PM
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement • GlobeNewswire Inc. • 09/03/2024 09:14:32 PM
- Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement • GlobeNewswire Inc. • 09/03/2024 09:06:29 PM
- Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference • GlobeNewswire Inc. • 08/28/2024 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:20:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:19:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:17:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 01:02:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:20:53 AM
- Royalty Pharma Reports Second Quarter 2024 Results • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:04:01 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:11 PM
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024 • GlobeNewswire Inc. • 07/19/2024 12:15:00 PM
- Royalty Pharma Declares Third Quarter 2024 Dividend • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:03:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:58:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 09:06:32 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/04/2024 09:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:57:02 PM
- Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 08:15:00 PM
- Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes • GlobeNewswire Inc. • 06/03/2024 09:15:27 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 06/03/2024 08:59:57 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 01:13:40 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 06/03/2024 12:39:32 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM